AQUANOVA RUS, CJSC
Shareholders in Portfolio Company
Investment Started: 2012
0.8 bln rubles
Co-investment by RUSNANO0.36 bln rubles
Solubilizates: creation of Russian industrial manufacturing of NovaSOL® solubilizates containing nanoparticles (product micelles) by means of international transfer of technology from AQUANOVA AG
The project is based on the technology from German company AQUANOVA AG for enclosing active organic substances into nanocapsules (micelles) about 30 nm in diameter. The technology provides improved activity and effectiveness of natural components along with favourable economic performance. In particular, more rational use of costly natural substance allows the reduction of its content in the final product (food ingredient) by 3-5 times at the same functionality, thereby significantly reducing the food ingredient prime cost.
The project provides the construction of a plant in Dubna to manufacture a wide range of micellized additive forms (vitamins and their precursors) already developed and patented by AQUANOVA AG. In addition, it is planned to create a laboratory for modification and optimization of the existing products.
The consumers of the project’s products include the companies from virtually all food industry segments (confectionery, oil and fat, dairy, fish and meat industries) using various food additives. Another potential consumers are pharmaceutical and cosmetic companies, as well as flexible packaging manufacturers.
Area of Application
- Production and sales of a wide range of ingredients obtained using the nano-level micellization technology.
- Food industry
- Pharmaceutical industry
- Cosmetic industry
- Flexible packaging manufacturers
The products of the project company have a number of advantages compared to native (non-micellized) substance forms. In particular, they demonstrate enhanced biological activity and penetrating ability, amphiphilicity (solubility both in aqueous and oil phase), high resistance to thermal, mechanical and chemical factors during production, resulting in higher effectiveness at lower dosages and, therefore, in higher economic performance.